Epithalon dosing debate: microdose vs. full cycle—what research actually shows

A recent TikTok clip asks a question that has been circulating in peptide communities: should Epithalon be dosed as a minimal microdose of 100 mcg per day, or as a full protocol cycle of 5–10 mg for 10–20 days? The creator notes that both approaches are being discussed online, and invites viewers to share their experiences. This reflects a broader confusion about how research peptides are used in self-experimentation contexts.

What the clip is claiming

The clip does not endorse a specific protocol but highlights a perceived divide in user-reported dosing strategies. It implies that there is a 'right' answer that can be determined by community consensus or anecdotal evidence. The underlying assumption is that more data from users will clarify which approach is 'actually working.'

What the research neighborhood actually covers

Epithalon (also spelled Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in Russia, studied primarily for its effects on telomere length and circadian rhythms. Published research, mostly from the 2000s, used subcutaneous injections at doses around 10 mg per day for 10 days in elderly patients, often repeated in cycles. Some animal studies used lower doses, but human data is limited and does not establish a microdose protocol. The peptide is thought to activate telomerase and influence pineal function, but clinical evidence is preliminary.

Limits, missing context, and what a 15-second clip cannot show

A short video cannot convey the nuances of dosing, reconstitution, or the difference between research and clinical use. The clip omits that Epithalon is not approved by regulatory agencies for any human use, and that 'protocols' circulating online are not derived from rigorous clinical trials. The 100 mcg microdose appears to be an extrapolation from animal studies or anecdotal reports, while the 5–10 mg cycle aligns more closely with published human studies, but those studies were small and not designed to establish optimal dosing. The clip also fails to mention that individual responses vary, and that self-administration carries risks.

How this maps to research compounds

Epithalon (Epitalon) is a catalog compound. The clip's reference to 'Epi-style peptides' points directly to this peptide. No other catalog compounds are relevant to this discussion. The dosing debate is specific to Epithalon, and the catalog lists it as a research-use peptide, not a therapeutic agent.

Research-use caveat

All peptides listed in the catalog are intended for research purposes only, not for human consumption or clinical use. The information presented here is for educational and scientific discussion. No dosing recommendations are made, and any use in humans is not supported by sufficient evidence. Always consult primary literature and regulatory guidelines before designing any study.

Open the full video fact-check page (transcript, takeaways, embedded clip).